Engineered antibodies act as targeted therapies in cancer treatment

Mani Mohindru, Amit K. Verma

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Over the last two decades cancer cure rates have not gone up as expected, and the effectiveness of chemotherapy has reached a plateau. This has prompted a search for targeted therapies with higher efficacy and lesser toxicities. Monoclonal antibodies against cancer cells offer targeted therapies with little or no toxicities against normal tissues. In this review we will discuss the concepts behind the development of monoclonal antibodies in cancer and their present status in the clinic. Specifically, we will discuss the clinical use of Rituximab (RituxanÓ), Trastuzumab (HerceptinÓ) and Bevacizumab (AvastinÓ) in various cancers and the key clinical trials that have led to their incorporation in cancer therapeutics.

Original languageEnglish (US)
Pages (from-to)943-947
Number of pages5
JournalIndian Journal of Pediatrics
Volume72
Issue number11
StatePublished - Nov 2005

Fingerprint

Antibodies
Neoplasms
Monoclonal Antibodies
Therapeutics
Clinical Trials
Drug Therapy
Bevacizumab
Trastuzumab
Rituximab

Keywords

  • Cancer cure
  • Chemotherapy
  • Monoclonal antibodies

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Engineered antibodies act as targeted therapies in cancer treatment. / Mohindru, Mani; Verma, Amit K.

In: Indian Journal of Pediatrics, Vol. 72, No. 11, 11.2005, p. 943-947.

Research output: Contribution to journalArticle

@article{fb09fa9bfe7d4f1bad12d4452584fbca,
title = "Engineered antibodies act as targeted therapies in cancer treatment",
abstract = "Over the last two decades cancer cure rates have not gone up as expected, and the effectiveness of chemotherapy has reached a plateau. This has prompted a search for targeted therapies with higher efficacy and lesser toxicities. Monoclonal antibodies against cancer cells offer targeted therapies with little or no toxicities against normal tissues. In this review we will discuss the concepts behind the development of monoclonal antibodies in cancer and their present status in the clinic. Specifically, we will discuss the clinical use of Rituximab (Rituxan{\'O}), Trastuzumab (Herceptin{\'O}) and Bevacizumab (Avastin{\'O}) in various cancers and the key clinical trials that have led to their incorporation in cancer therapeutics.",
keywords = "Cancer cure, Chemotherapy, Monoclonal antibodies",
author = "Mani Mohindru and Verma, {Amit K.}",
year = "2005",
month = "11",
language = "English (US)",
volume = "72",
pages = "943--947",
journal = "Indian Journal of Practical Pediatrics",
issn = "0972-9607",
publisher = "Springer India",
number = "11",

}

TY - JOUR

T1 - Engineered antibodies act as targeted therapies in cancer treatment

AU - Mohindru, Mani

AU - Verma, Amit K.

PY - 2005/11

Y1 - 2005/11

N2 - Over the last two decades cancer cure rates have not gone up as expected, and the effectiveness of chemotherapy has reached a plateau. This has prompted a search for targeted therapies with higher efficacy and lesser toxicities. Monoclonal antibodies against cancer cells offer targeted therapies with little or no toxicities against normal tissues. In this review we will discuss the concepts behind the development of monoclonal antibodies in cancer and their present status in the clinic. Specifically, we will discuss the clinical use of Rituximab (RituxanÓ), Trastuzumab (HerceptinÓ) and Bevacizumab (AvastinÓ) in various cancers and the key clinical trials that have led to their incorporation in cancer therapeutics.

AB - Over the last two decades cancer cure rates have not gone up as expected, and the effectiveness of chemotherapy has reached a plateau. This has prompted a search for targeted therapies with higher efficacy and lesser toxicities. Monoclonal antibodies against cancer cells offer targeted therapies with little or no toxicities against normal tissues. In this review we will discuss the concepts behind the development of monoclonal antibodies in cancer and their present status in the clinic. Specifically, we will discuss the clinical use of Rituximab (RituxanÓ), Trastuzumab (HerceptinÓ) and Bevacizumab (AvastinÓ) in various cancers and the key clinical trials that have led to their incorporation in cancer therapeutics.

KW - Cancer cure

KW - Chemotherapy

KW - Monoclonal antibodies

UR - http://www.scopus.com/inward/record.url?scp=28644437961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28644437961&partnerID=8YFLogxK

M3 - Article

C2 - 16391449

AN - SCOPUS:28644437961

VL - 72

SP - 943

EP - 947

JO - Indian Journal of Practical Pediatrics

JF - Indian Journal of Practical Pediatrics

SN - 0972-9607

IS - 11

ER -